FORT LAUDERDALE, Fla., April 5, 2011 /PRNewswire/ -- OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that its TrialMaster® suite of applications and IVRS technology has been chosen by a prominent biotechnology company to manage their clinical data management and randomization needs for 4 key clinical trials. All 4 studies, leveraging OmniComm's Software-as-a-Service (SaaS) rapid-deployment model, will be put into production by the end of May.
"We are honored to be chosen by this biotech firm to manage so many key studies," said Stephen Johnson, President & COO of OmniComm. "Our past experience with this company, and the trust that we've built with them to get these studies up and running under such tight timelines, were pivotal in their selection of OmniComm. We look forward to the challenge."
OmniComm has also recently become a Society for Clinical Data Management CCDM® partner, an achievement that is only bestowed upon companies that are committed to quality clinical data management and Certified Clinical Data Manager (CCDM) credentialing. Qualifying companies must have at least 10 certified CCDMs or 25% of CDMs must have achieved certification.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm Systems, Inc.
SOURCE OmniComm Systems, Inc.